CD8A and neoplasm: The above data suggest that the PRGN-2009 HPV vaccine construct (no. 4) was the most efficacious both in vitro by IFN-γ ELISA and in vivo by decreased mouse tumor volumes and tumor weights at the end of the study, and it promoted increased CD8+ T cell infiltration.